Sign in Subscribe

kras

A collection of 116 issues

Pulmonary artery enlargement observed during bevacizumab therapy in KRAS-mutant colon cancer

Skip to content The CRC Digest Pulmonary artery enlargement observed during bevacizumab therapy in KRAS-mutant colon cancer A retrospective study of 150 patients with KRAS-mutant colon cancer investigated whether serial thoracic CT demonstrates progressive enlargement of the main pulmonary artery during bevacizumab-based chemotherapy. (Cancer Chemother Pharmacol) This content is informational

CRC Research Update — September 16, 2026

Today's colorectal cancer research highlights

Critical review outlines biomarker-guided treatment selection in metastatic CRC

Skip to content The CRC Digest Critical review outlines biomarker-guided treatment selection in metastatic CRC A structured narrative review separately examines mismatch repair-deficient/MSI-H and microsatellite-stable disease, distinguishing established treatments from investigational strategies based on molecular alterations including BRAF V600E and HER2. (Crit Rev Oncol Hematol) This content is informational

Oral KRAS G12D inhibitor GFH375 evaluated in phase 1 trial

Skip to content The CRC Digest Oral KRAS G12D inhibitor GFH375 evaluated in phase 1 trial GFH375 targets both GTP-bound and GDP-bound states of KRAS G12D proteins, the most prevalent RAS mutation in solid tumors, in patients with advanced colorectal cancer, pancreatic cancer, and non-small cell lung cancer. (Nat Med)

Phase 1 trial evaluates oral KRAS G12D inhibitor GFH375 in advanced solid tumors

Skip to content The CRC Digest ▸ TREATMENT Phase 1 trial evaluates oral KRAS G12D inhibitor GFH375 in advanced solid tumors A phase 1 dose-escalation trial evaluated GFH375, an oral compound that targets both active and inactive states of KRAS G12D proteins, in patients with advanced solid tumors harboring the KRAS

CRC Research Update — September 14, 2026

Today's colorectal cancer research highlights

Pooled Analysis Examines Prognostic Value of KRAS Mutations and Liver Metastases

Skip to content The CRC Digest Pooled Analysis Examines Prognostic Value of KRAS Mutations and Liver Metastases A pooled analysis of third-line placebo-controlled trials from the ARCAD CRC Database evaluated the prognostic impact of liver metastases and KRAS mutations in metastatic colorectal cancer patients. (Clinical Colorectal Cancer) This content is

CRC Research Update — September 13, 2026

Today's colorectal cancer research highlights

CRC Research Update — September 09, 2026

Today's colorectal cancer research highlights

KRAS Mutations Shape Immunosuppressive Tumor Environment

Skip to content The CRC Digest ◇ RESEARCH KRAS Mutations Shape Immunosuppressive Tumor Environment A review describes how KRAS mutations—present in approximately 52% of colorectal cancers—actively create an immunosuppressive tumor microenvironment, presenting a major barrier to both targeted therapy and immunotherapy. (Frontiers in Oncology) This content is informational only